A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)
Phase of Trial: Phase III
Latest Information Update: 29 Oct 2019
Price : $35 *
At a glance
- Drugs Atropine (Primary)
- Indications Myopia
- Focus Registrational; Therapeutic Use
- Acronyms CHAPERONE
- Sponsors Eyenovia
- 29 Oct 2019 According to an Eyenovia media release, the company expects to complete enrollment in the trial by 2020.
- 02 Oct 2019 According to an Eyenovia media release, new usability data generated from this study will be presented at an upcoming medical meeting (October 2019).
- 04 Jun 2019 According to an Eyenovia Inc. media release, this study along with the previous studies will be used for FDA approval of MicroPine.